OLD Mission Capital LLC Purchases 1,687 Shares of Takeda Pharmaceutical Company Limited (NYSE:TAK)

OLD Mission Capital LLC boosted its position in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK) by 13.7% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 13,977 shares of the company’s stock after buying an additional 1,687 shares during the quarter. OLD Mission Capital LLC’s holdings in Takeda Pharmaceutical were worth $185,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in TAK. Blair William & Co. IL raised its stake in shares of Takeda Pharmaceutical by 8.1% during the fourth quarter. Blair William & Co. IL now owns 12,199 shares of the company’s stock valued at $162,000 after acquiring an additional 913 shares during the last quarter. Sage Rhino Capital LLC raised its position in Takeda Pharmaceutical by 14.9% during the 4th quarter. Sage Rhino Capital LLC now owns 11,840 shares of the company’s stock valued at $157,000 after purchasing an additional 1,538 shares during the last quarter. Kovitz Investment Group Partners LLC lifted its holdings in Takeda Pharmaceutical by 7.0% in the 3rd quarter. Kovitz Investment Group Partners LLC now owns 25,456 shares of the company’s stock worth $362,000 after buying an additional 1,670 shares during the period. Aaron Wealth Advisors LLC grew its position in shares of Takeda Pharmaceutical by 7.2% in the 4th quarter. Aaron Wealth Advisors LLC now owns 25,000 shares of the company’s stock worth $331,000 after buying an additional 1,670 shares during the last quarter. Finally, EverSource Wealth Advisors LLC increased its stake in shares of Takeda Pharmaceutical by 51.8% during the fourth quarter. EverSource Wealth Advisors LLC now owns 5,190 shares of the company’s stock valued at $69,000 after buying an additional 1,770 shares during the period. Hedge funds and other institutional investors own 9.17% of the company’s stock.

Takeda Pharmaceutical Trading Down 2.3 %

Shares of TAK opened at $14.05 on Wednesday. Takeda Pharmaceutical Company Limited has a 1-year low of $12.58 and a 1-year high of $15.37. The firm has a market capitalization of $44.69 billion, a price-to-earnings ratio of 35.11, a PEG ratio of 0.24 and a beta of 0.39. The firm’s 50-day moving average price is $14.40 and its 200-day moving average price is $13.91. The company has a current ratio of 1.31, a quick ratio of 0.72 and a debt-to-equity ratio of 0.63.

Takeda Pharmaceutical (NYSE:TAK) last posted its quarterly earnings data on Thursday, January 30th. The company reported $0.42 earnings per share for the quarter, beating the consensus estimate of $0.34 by $0.08. Takeda Pharmaceutical had a return on equity of 9.39% and a net margin of 4.53%. Sell-side analysts anticipate that Takeda Pharmaceutical Company Limited will post 1.64 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, Morgan Stanley raised Takeda Pharmaceutical from an “equal weight” rating to an “overweight” rating in a research note on Wednesday, April 2nd.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.